Switching from Beraprost to Selexipag in the Treatment of Pulmonary Arterial Hypertension: Insights from a Phase IV Study of the Japanese Registry (The EXCEL Study: EXChange from bEraprost to seLexipag Study)

Pulmonary arterial hypertension (PAH) remains a significant challenge in cardiology, necessitating advancements in treatment strategies. This study explores the safety and efficacy of transitioning patients from beraprost to selexipag, a novel selective prostacyclin receptor agonist, within a Japane...

Full description

Bibliographic Details

Published in:	Pharmaceuticals
Main Authors:	Yuichi Tamura, Hiraku Kumamaru, Ichizo Tsujino, Rika Suda, Kohtaro Abe, Takumi Inami, Koshin Horimoto, Shiro Adachi, Satoshi Yasuda, Fusako Sera, Yu Taniguchi, Masataka Kuwana, Koichiro Tatsumi
Format:	Article
Language:	English
Published:	MDPI AG 2024-04-01
Subjects:	drug transition study pulmonary arterial hypertension pulmonary vascular resistance selexipag beraprost
Online Access:	https://www.mdpi.com/1424-8247/17/5/555